A vaccine adjuvant is a substance that is added to improve the effectiveness of a vaccine. Adjuvants are immune potentiators that can elicit an early innate immune response to help in the generation of strong and long-term protection against infection. The adjuvant can enhance the immune system so that less vaccine is required.! The development of a specific immune response (humoral or cell-mediated) can also be determined by the choice of the adjuvant.
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ex-Galactosylceramides are a family of molecules that have been of particular interest over the past few years due to their significant immunomodulating properties. They and their analogues have displayed adjuvant activity2-5 and have been successful in enhancing the immune response of both live recombinant vaccines and inactivated vaccines against a wide range of diseases including malaria,6 HIV/ viral infection and tumours. s Mice immunized with proteins and ex-galactosylceramides develop antibody titers 1-2 logs higher than those induced by proteins alone. Also, single intranasal administration of ex-galactosylceramides with inactivated influenza virus has resulted in long-term protection. 9 ex-Galactosylceramides stimulate the immune system by a distinct mechanism, they function by stimulating cytokine release of Natural Killer T (NKT) cells that in turn activates the adaptive immune response. Recently, it has been shown that NKT cells can modulate dendritic cells (DCs) and B-cell activity, and can increase DC-induced B-and T-cell responses. Activation of NKT cells by ex-galactosylceramides can therefore elicit higher frequencies of memory B cells and higher antibody responses to boost immunizations. 1O -!6 As such, extensive research has been carried out to gain an understanding of ex-galactosylceramides, of their structure, mechanism of action and the reason for their potency. The following review is a summary of the literature that has been published on ex-galactosylceramides, reporting on the developments in their chemical synthesis, on the alterations of the original structure and on the resulting bioactivity of these molecules.
Introduction

History of ex-GalCer
A small family of galactosylceramides was isolated from the Okinawan sponge, Agelas Mauritianus, by researchers at Kirin Pharmaceuticals in 1993. These galactosylceramides became of particular interest as extracts from Agelas M auritianus displayed anti-tumour properties in murine models. Agelasphin-9b, one of the galactosyIceramides, as shown in Fig. 1 , displayed potent in vivo anti-tumour activity. 17 Agelasphin-9b KRN7000 = a-GalCer Parallel biological and synthetic studies revealed that the potency of Agelasphin-9b did not rely on the ex-hydroxy group in the fatty acyl residue, nor the branching in the phytosphingosine chain. Thus, KRN7000 (Fig. I ) emerged as a potent lead compound which is a powerful immunostimulant in mammals. KRN7000 is commonly known as ex-galactosyIceramide (ex-GaICer) and will be referred to as ex-GalCer in this article.
Structure of o:-GalCer ex-GaICer, [(2S,3S,4R)-I -0-( ex-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol]
, comprises a galactosyl sugar ex-linked to a ceramide moiety composed of a long-chain amino alcohol, D-ribo-phytosphingosine, that is N-acylated with a 26-carbon fatty acid. It should be noted that the glycosidic bond of this glycolipid is ex-configurated, while mammalian glycolipids typically exist in the ~-anomeric form. 18 ,19 ex-Linked galactosyIceramides have only been found in cancer 20 and foetaf ' cell lines to date. Furthermore, the ceramide moiety of ex-GalCer differs from the norm containing a dihydroxy structure instead of a 4,5-trans carbon-carbon double bond that is usually found,z2 The recognition of a marine derived ex-GalCer by a mammalian receptor resulting in such a powerful immune response is very surprising.
Mode of activation
ex-GalCer binds with high affinity to CD! d, a major histocompatibility complex (MHC) class I-like molecule on the surface of antigen-presenting cells (APCs). The ex-GalCerjCDld complex is then presented to NKT cells (natural killer T cells), and upon recognition, the rapid secretion of Th! (T helper I) and Th2 (T helper 2) cytokines occurs. Th! cytokines include IFN-y, IL-2 and TNF-ex, and the production of these cytokines is associated with antitumour,23 antiviraljbacterial 24 and adjuvant 2 -5 effects of ex-GaICer. Th2 cytokines include IL-4, IL-lO and IL-13, and these cytokines are thought to be related with the amelioration of certain autoimmune diseases such as type I diabetes 25 and animal encephalomyelitis. 26 Activation of NKT cells by Cl-GalCer can thus enhance or suppress immune responses. 27 ,28 However, Cl-GalCer failed a Phase I study in the treatment of solid tumours, possibly due to the reciprocal inhibition exhibited by Thl and Th2 cytokines, as Cl-GalCer produces equal quantities of IFN-y and IL_4. 29 In order to optimise the potential medicinal effects of Cl-GalCer it is necessary to bias either an immunostimulatory or a pro inflammatory response. Time course cytokine release studies in mice have shown that once the NKT cell is activated by Cl-GaICer, IFN-y cytokine release levels (Thl response) peak after 12 h, while IL-4 levels (Th2 response) peak within 2 h. 30, 31 Therefore, the stability of the Cl-GaICer/CDld complex is currently a focus point in the design of potent Cl-GalCer analogues. Increasing the binding between the glycolipid and COld, and the stability of the complex, could promote greater levels of IFN-y release with a view to promoting Th I response. Conversely, a less stable Cl-GaICer/CDld complex could shorten NKT stimulation times resulting in a biased Th2 response. 32 ,33 
Binding with CD1d
Cl-GalCer binds with high affinity to both mouse COld (mCDld) and human COld (hCDld) and specifically activates the main population of COld restricted T cells, i.e. iNKT cells. 3 4-36 Recently, Cerundolo and coworkers reported the X-ray crystal structures of Cl-GalCer bound to human COld molecules,37 which shows that the lipid chains of the glycolipid are buried in the two grooves in COld composed largely of hydrophobic amino acids, while the galactose residue is largely exposed for the recognition by the T cell receptor. 37, 38 The crystal structures revealed also an "anti" dihedral angle of '" 170 0 for the CD I d-bound conformation of the linker region between the galactose and the ceramide. 37 ,38 The phytosphingosine chain of the glycolipid binds in the hydrophobic C' pocket of COld which ideally accomodates 18 carbons, while the longer acyl chain binds in the other hydrophobic A' pocket that can accomodate up to 26 carbons. Lipids that bind to COld usually contain relatively long chains of From the crystal structure, it is not immediately apparent how the lipid chain length and the sugar moiety influence NKT cell responses. However, several hydrogen bonds identified between human COld and Cl-GalCer at the junction of the two alkyl chains and the polar head group did answer theoretically some of the structure-activity data derived from Cl-GalCer analogues (vide infra). The 2-0H of the galactose ring, which is crucial for the antigenicity of Cl-GaICer, is hydrogen-bonded to Aspl5J. The 3-0H of the sphingosine chain, shown to be necessary for mouse NKT cell recognition, forms a hydrogen bond with Asp80, and the anomeric oxygen forms the third hydrogen bond to Thrl54. These bonds serve to anchor Cl-GalCer in a distinct orientation and position it in the lipid-binding groove. In addition, the 2-, 3-and 4-0H groups of the galactose ring interact with the invariant TCR Cl-chain making hydrogen bonds with the corresponding amino acids. 
Syntheses of a;-GaICer
First synthesis of a;-GaICer
Initially, six kinds of agelasphins with <x-GalCer structure were isolated from the marine sponge Age/as mauritianus as active substances prolonging the life span of mice intraperitoneally inoculated with Bl6 mouse melanoma celis. 41 ,42 Of them, agelasphin-9b showed potent activity when tested in vivo on murine tumour cells. 17 The total synthesis of Agelasphin-9b was carried out by Morita et al. in 1993. 43 Soon after, the first synthesis of <x-GaICer along with several other analogues was reported by Morita et al., 17 in which a method similar to that used previously by Koike et al. 44 was employed to synthesise the ceramide building block and a glycosyl fluoride was used as thegalactosyl donor, as shown in Scheme 1. Previously, efficient syntheses of phytosphingosines and their transformation into ceramides had also been reported by Schmidt 4 5-47 amongst others.
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Synthesis of a;-GaICer by glycosylation of phytosphingosine or ceramide derivatives
When designing a synthetic route to <x-GalCers a number of factors must be considered, for instance, i) how to introduce the stereogenic centers in the phytosphingosine chain; ii) when to introduce the fatty acid chain; iii) how to control the <x-stereochemistry of the glycosidic linkage. A wide variety of different synthetic strategies have been explored in optimising the synthesis of <x-GaICer, in which the glycosidation reaction is often the key step during the synthesis. Protecting groups often play important roles in modulating the reactivity of glycosyl donors and acceptors and in directing the stereochemistry of glycosidation reactions. <x-Directing protecting groups have been successfully used in the formation of the essential <x-glycosidic linkage in <x-GalCer. For example, Schmidt and coworkers took advantage of the <x-directing effect of a 4,6-0-benzylidene group on the galactosyl trichloroacetimidate donor to obtain high yields of the desired glycosylated product, 52 as shown in Scheme 2. It is also worth noting that a 1,3,4-0-unprotected phytosphingosine derivative was used as the acceptor and the glycosidation step is highly regio-and stereo-selective. This is very attractive as it reduced the protection-deprotection steps required in the synthesis. For this synthesis it was more efficient to introduce the azide after the glycosylation, as the electron withdrawing mesyl group is thought to increase the reactivity difference between the hydroxy groups, favouring attack at the primary hydroxy group. Later Wong et al. investigated a number of gIycosylation methods in the synthesis of ex-galactosyIceramide, but also found the above benzylideneprotected trichloroacetimidate donor to be the most successful. 53 Recently Kiso et al. reported that 4,6-di-tert-butylsilylene (DTBS)-protected galactosyl donors are powerful ex-galactosylating agents,54 that were employed to synthesise different ex-galactosides, including ex-GaICer. 55 As shown in Scheme 3, the ceramide derivative was effectively glycosylated with the DTBS-protected galactosyl trichloroacetimidate in high stereoselectivity to give the fully protected ex-GalCer in good yield, which after deprotection afforded the target molecule. Notably, the excellent ex-stereoselectivity in the synthesis was achieved in the presence of a neighbouring participating group. Almost at the same time, the strong stereodirecting effect of the DTBS group was afso utilized by Painter and coworkers to synthesise ex-GalCer and its analogues, in which azidophytosphingosine derivatives 47 were used as acceptors in the glycosidation reactions. 56 Glycosyl iodides have been applied recently to the concept of in situ anomerization to prepare different ex-glycosides. The concept was introduced initially by Lemieux using glycosyI bromides. However, compared Scheme 3 Kiso's synthesis of a-GalCer with glycosyl bromides, the reactions with glycosyl iodides are orders of magnitude faster, proceeding quantitatively, with exclusive formation of <x_anomers. 57 -59 This methodology was effectively used by Gervay-Hague et al. to synthesise <x-GaICer and its analogues, as exemplified in Scheme 4.
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In the glycosidation step, a highly reactive ~-glycosyl iodide was generated by inversion of the <x-anomeric iodide using tetrabutylammonium iodide (TBAI) and reacted with the electron-rich azidophytosphingosine intermediate to furnish the desired <x-product in excellent yield and stereoselecti vi ty . Not only the glycosyl donor but also the acceptor play an important role in glycosidation reactions. Although direct glycosylation of ceramide derivatives was occasionally used to construct glycosylceramides, the glycosidation reactions led often to a low product yield as the amide group can participate as nucleophile in glycosidation reactions or it can deactivate the primary hydroxy group through unfavourable hydrogen bonding interaction. 61 ,62 The nucleophilicity of the primary hydroxy group was thought to be reduced by donating partially the lone pair of the oxygen to the amide hydrogen. Hence, Gervay-Hague et al. used as highly reactive glycosyl donor per-O-silylated galactosyl iodide to compensate for the low reactivity of ceramide compounds in the convergent synthesis of <x-GaICers. 63 Even then, microwave energy was required to drive the glycosidation reaction to give a good yield of <x-GaICer, as shown in Scheme 4.
Inspired by Gervay-Hague's work, another effort to improve the yield of the direct glycosylation of ceramide derivatives was made by CastiII6n and coworkers. 64 They introduced a stannyl ether group onto the ceramide moiety with a view to increasing the nucleophilicity of the oxygen atom, thereby enhancing the reactivity of the ceramide. The glycosidation reaction was carried out under optimized conditions with the same galactosyl iodide as donor. After hydrolysis of protecting groups by using acidic resin, et-GalCer was obtained in very high yield and complete et-selectivity. (Scheme 5). However, due to the above-mentioned low reactivity of ceramide derivatives, less convergent routes were more frequently adopted (vide supra) to synthesise et-galactosylceramides with azidophytosphingosine derivatives 47 as glycosyl acceptors. The azido group was then reduced to the amine after glycosidation reaction to facilitate introduction of the fatty acid. C"H'9 66%
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Synthesis of et-GalCer by other strategies
Recently Ronchetti and Ito reported almost at the same time strategies for the synthesis of et-galactosylceramides, in which azidothreitol derivatives were both prepared as key intermediates and the phytosphingosine chains were elaborated after glycosylation reactions,66,67 Ronchetti et al. also took advantage of the in situ anomerization protocol for the glycosidation reaction to build up the ex-glycosidic linkage, in which the galactosyl bromide was generated in situ using Appel's reagent (Scheme 7). The sphingosine chain was then extended using Carreira alkynylation, which had previously been successfully exploited in the synthesis of the sphingoid skeleton. 68 The addition reaction was carried out in the presence of Zn(OTfh and (-)-N-methylephedrine was used as a chiral additive to ensure the desired stereoselectivity of the reaction.
Ito et al. carried out the glycosidation reaction using a thioglycoside and a tritylated azidothreitol intermediate as the glycosyl donor and acceptor, respectively. The reaction proved successful with MeOTf as promoter, giving the glycosidation product in good yield and complete ex-selectivity (Scheme 8). It was then converted to the Weinreb's amide and reacted with tetradec-I-yne in the presence of BuLi to give the ynone intermediate, which was subsequently reduced stereo selectively with Corey's CBS system to afford the propargylic alcohol.
The advantage claimed for these strategies is that they allow the synthesis not only of ex-GalCer itself but also of different glycolipids with variations in the structure of the sphingoid base. Therefore, these strategies are attractive for the development of ex-GalCer analogues with various structural motifs in the lipid chain.
More recently, a similar strategy was reported by Panza and coworkers for the synthesis of ex-GaICer, in which a series of ex-GalCer analogues were also readily obtained. 69 The synthesis involved a disaccharide building block, namely 5-galactosyl lyxoside, which was prepared from tetra-O-benzyl-Dgalactose and allyl 2,3-0-isopropylidene-D-lyxofuranoside, as shown in Scheme 9. It was then transformed into ex-GalCer and its analogues by Wittig reaction and standard synthetic procedures. Thus, in this strategy the lipid chain was also elaborated after glycosylation reaction. It should be mentioned that the D-lyxofuranose motif had previously been used by Lin et al. 70 to synthesise phytosphingosine derivatives, and eventually ex-GalCer since it contains the requisite stereochemistry for the generation of phytosphingosine. As mentioned in the introduction, the stability of the ex-GaICer/CDld complex seems to significantly influence the profile of cytokine release.
The lipid chain length of ex-GalCer is therefore a very important aspect for designing ex-GalCer analogues as the chains are strongly involved in the binding with CDld. OCR, a truncated analogue of ex-GaICer, was first reported by Yamamura et al. 30 As shown in Fig. 2 , the phytosphingosine moiety of this molecule is a 3,4-dihydroxy nonane chain as opposed to the 3,4-dihydroxy octadecane chain of ex-GalCer and its fatty acyl chain is two carbon atoms shorter than ex-GalCer (for structural variations, see refs. 15, 86) . Yamamura reported that this ex-GalCer analogue, although up to 10 times less active than ex-GalCer in inducing cell proliferation, produced less IFN-y but more IL-4 cytokine in vitro. The shift of the cytokine release profile resulted in a Th2 biased response in vivo, suggesting that it could be used as a possible therapeutic agent for autoimmune diseases such as multiple sclerosis. Later Miyake et al. reasoned that the OCR/CDld complex is too unstable to interact well with NKT cell receptors; the shorter-chain lipids form CDld/glycolipid complexes with shorter halflives,71 and INF-y release by NKT cells requires longer stimulation by CD 1 d/glycolipid complexes than for IL-4 release. The lower stability of the complex is probably due to the fact that the alkyl chain is not filling the binding groove. 37 As previous methods used for the synthesis of ex-GalCer were claimed to provide lower yields in the synthesis of the shorter chained OCR molecule, an alternative synthesis was developed by Annoura and coworkers. 72 As outlined in Scheme 10, the epoxide containing the necessary chiral centres was first prepared from o-arabinitol and alkylation of this epoxide facilitated introduction of the truncated sphingosine chain in almost quantitative yield. Subsequently, halide ion catalyzed glycosidation was carried out with benzyl protected galactosyl bromide as the donor to provide the ex-glycosidic linkage, and indeed the ex-product was isolated exclusively in very good yield. This method is attractive as it turned out to be amenable for largescale synthesis.
In order to investigate the effect of lipid chain length on the cytokine release profile from NKT cells, Savage and coworkers synthesised recently a series of ex-GalCer analogues with different length of phytosphingosine and fatty acyl chains (Scheme 11). 73 The phytosphingosine chains were prepared from Garner's aldehyde, which was first converted into alkenes by Wittig reaction following literature procedures,74 and then dihydroxylation with OS04 and NMO was performed to give the desired o-ribo and L-arabino diols in 2: 1 ratio as readily separable mixtures. The o-ribo series was Scheme 11 Savage's synthesis of a;-GaICer analogues including OCH subsequently deprotected and coupled with various carboxylic acids to generate the ceramide acceptors, which were then glycosylated with galactosyl bromide to give rise to the correponding ex-galactosylceramides. The biological assays of these glycolipids show that there is indeed a correlation between lipid chain length and cytokine release profiles, and the chainshortened glycolipids bias cytokine release toward Th2 response. In addition, the authors pointed out that loss of too much lipid content could result in complexes with COld too unstable to interact well with NKT cell receptors.
Many other studies show that ex-GalCer analogues containing an 18-carbon phytosphingosine chain but shorter fatty acyl chains also release a greater IL-4 to INF-y ratio of cytokines. As previously mentioned, the shift of the cytokine release pattern is most likely due to the formation of a less stable glycolipid/CD Id complex. The immunostimulatory effect of another ex-GalCer analogue 56 synthesised by Painter et al. also corroborated this activation model. They synthesised an ex-galactosylceramide with a phytosphingosine chain containing two extra carbons and a fatty acyl chain equivalent to OCH; this analogue proved to be less potent than ex-GaICer, but did not display the stronger Th2 bias of OCH.
Modification of functional groups on the phytosphingosine chain
In addition to the modification of the lipid chain length, modification of the functional groups present at the lipid chains were studied for the structureactivity relationships of ex-GaICer. Koezuka and coworkers reported that an ex-GalCer analogue which had neither the 3-0H nor the 4-0H of the sphingosine resulted in no activity when used in mixed leucocyte reaction (MLR) in vitro, while when only the 4-0H group was missing, the compound, i.e. the sphinganine analogue of ex-GaICer, was capable of initiating a significant response. 75 Recently, Howell et al. also synthesised sphinganine analogues of ex-GalCer and OCH from Weinreb amides, as shown in Scheme 12, with the view to creating readily accessible ex-GalCer analogues that would display similar activity as their parent compounds. 76 The preparation of sphinganine derivatives (aminodiols) is often easier than the synthesis of phytosphingosines (aminotriols). Thus, the ceramide intermediates were prepared as the acceptors and glycosylated with ~-tetrabenzylgalactosyl fluoride in the presence of AgCl0 4 and SnCh to give the corresponding glycosides in high ex-selectivities but pretty low yields. These analogues, though not as potent as the corresponding phytosphingosine compounds, were found to be comparable in activity in inducing the release of IL-2, IL-4 and IFN-y as the OCH analogue and displaying a cytokine bias similar to that seen with OCH.
Biological activities of other analogous sphinganine-containing ex-galactosylceramides also indicated that the 4-0H group of the phytosphingosine chain did not show a noticeable effect on the activity of the molecules. 17, 77 s-BuMGCI (2 e9). Very recently, Dubreuil et al. also synthesised a sphinganine analogue of a-GalCer, as outlined in Scheme 13, and this compound was also capable of inducing potent cytokine responses, comparable to those of a-GalCer, both from human NKT cells in vitro and from the murine counterpart in vivo. 78 The key step in the synthesis is the olefin cross metathesis reaction, which could potentially provide ready access to a large range of sphinganine analogues of a-GaICer. The drawback of the synthesis is the low a-selectivity of the glycosidation step, giving the precursor for the metathesis reaction in a: p 2: I selectivity.
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Bno~ + a-GalCer analogues with a sphingosine chain, characterized by a double bond between C4 and CS, retained also their ability to stimulate NKT cells, suggesting that the 4-0H group is indeed not critical for CD Id presentation. 6o In addition, another interesting work verifying this argument is the synthesis and in vivo evaluaton of 4-deoxy-4,4-difluoro-a-GalCer reported by Linclau and coworkers. 79 Starting from commercially available phytosphingosine, they first synthesised 4-deoxy-4,4-difluoro azidosphingosine intermediate (Scheme 14), which was then glycosylated with the galactosyl trichloroacetimidate donor 52 and elaborated subsequently to furnish the target molecule. The glycosidation step is highly regioselective and a-selective, giving the desired a-glycoside in very good yield and no p-isomer was detected. The biological data of this a-GalCer analogue confirm that the 4-0H is not required for activity and that replacement with a gemdifluoro group at that position is allowed.
In contrast, the 3-0H group of the sphingosine chain is essential for the bioactivities of a-GalCer as mentioned above. 36 ,80-82 It is found that this hydroxy group is not only involved in a hydrogen bond with Asp80 residue of the CDld al helix, but also in a hydrogen bond to the side chain of Arg9Sa of the TCR CDR3a 100p.4o As such, it plays an important role in both anchoring the ligand into the binding groove and interacting with TCR. 83 Therefore, eradication of the 3-0H group of the sphingosine chain would result in the loss of immunostimulatory activity of a-GaICer. The three stereo genic centres on the phytosphingosine chain of ex-GalCer could theoretically give rise to eight stereoisomers. Chung et al. synthesised recently a complete set of these eight stereoisomers in order to investigate the SAR of ex-GaICer. The synthesis involved the preparation of all eight corresponding ceramide intermediates from L-and D-serine, and their glycosylation with tetrabenzylgalactosyl trichloroacetimidate (Scheme 15). The biological data of these diastereoisomers indicated that the stereochemistry of the amino group and 3-0H group was both crucial for the activity, but the configuration of the amino group was significantly more important than the configuration of the 3-0H group, and that the alteration of the stereochemistry of the 4-0H group did not seem to harm the activity. 84 Calenbergh and coworkers also reported the synthesis of three similar diastereoisomers, in which a Mitsunobu reaction was carried out to invert the configuration of either 3-0H or 4-0H of commercially available phytosphingosine, and a trichloroacetimidate donor was employed as well to build up the <x-glycosidic bond. 8s Interestingly, the subsequent in vitro test of these compounds showed that a truncated diastereoisomer of <x-GaICer induced similar levels of IFN-y and IL-4 compared with <x-GaICer, suggesting that the alteration of the stereochemistry of the phytosphingosine chain could result in a different cytokine release profile.
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In addition, Wong et al. introduced a phenyl group at the end of truncated phytosphingosine chains without disrupting the functional groups. The resultant <x-GaICer analogues displayed a significantly greater induction of IFN-y and hence anticancer efficacy than found for <x-GaICer. 86 <x-GaICer analogues possessing azetidine or pyrrolidine ring in the phytosphingosine chain were also synthesised recently and assayed as immunostimulants. 87 Unfortunately, none of these conformationally restricted analogues could induce NKT cells to produce preferentially either Th1 or Th2 cytokines, and they all exhibited weaker stimulatory activities than <x-GaICer. Thus, introduction of restraining elements into the phytosphingosine chain does not seem to be beneficial for its activity.
Modification of the fatty acyl chain
Apart from modifying the functional groups on the phytosphingosine chain, significant attention has also been paid to the convenient modification of the fatty acyl chain in the past decade. Wong and co workers synthesised a variety offatty acyl chain analogues based on CD I d/glycolipid structures. 88 They introduced different aromatic groups into the fatty acyl chain with a view to make tighter CD Id-binding glycolipids as crystal structures showed that the CDld A' binding groove was lined with numerous aromatic sidechain residues. These analogues were expected to introduce extra aromatic interactions which could increase the stability of the CDld/glycolipid complex, thereby favoring the induction of Th 1 cytokines. Indeed, some of these analogues with proper fatty acyl chain length, as shown in Fig. 3 , were four times more potent than <x-GaICer and biased to IFN-y secretion.
Computational docking of these analogues in the hCDld hydrophobic groove was also conducted, and the results indicated that their binding mode did not vary much from the crystal structure of <x-GaICer bound to hCD 1 d. In each case, the phytosphingosine chain was bound to the F' pocket and the A' pocket was occupied by the modified fatty acyl chain with the galactose headgroup presented in nearly the same conformation. Additional binding force between the terminal phenyl group and Tyr73 or Trp40 was proposed. 88 Prior to Wong's work, Porcelli and coworkers synthesised a series of o:-GalCer analogues with unsaturated fatty acyl chains and investigated the effect on NKT cell activation in order to develop potent NKT cell agonists that may have superior properties for the treatment of autoimmune and inflammatory diseases. 89 Acyl chains with 20 carbons and varying degrees of unsaturation were coupled onto an o:-galactosyl phytosphingosine core structure to generate these unsaturated analogues. One analogue containing two double bonds on the fatty acyl chain, as shown in Fig. 4 , potently induced a Th2 biased cytokine response, with diminished IFN-y production and reduced NKT cell expansion. The change in the NKT cell response could be attributed to the slightly enhanced rigidity of the molecule, which would weaken the binding with CDld, because the flexibility required for o:-GalCer acyl chain to fit tightly into the A' pocket of CDld should be reduced due to the presence of double bonds. Based on Porcelli's work, very recently, Howell and co workers investigated whether an o:-GalCer analogue carrying the above unsaturated fatty acyl chain and a sphinganine chain of the same length of OCH could result in even further biasing to a Th2 response. 90 For comparison purposes, they also synthesised the saturated version of this analogue. Surprisingly, the biological evaluation demonstrated that this compound was slightly less stimulatory than the saturated compound. This was in contrast to the effect seen with the Porcelli compound where the saturated compound was more potent. Therefore, in this case the unsaturated fatty acyl chain offered no advantage in terms of bioactivities.
The crystal structure of o:-GalCer/hCDld shows that the o:-GalCer amide NH is perfectly lined up to form a hydrogen bond with the OH group of the adjacent Thr 154 residue. To investigate if this hydrogen bond plays an important role in modulating the stability of the <x-GalCerjCD I d complex, Linclau et al. modified very recently the interaction by introducing a gem-difluoro group onto the <x-position of the fatty acyl chain,91 as shown in Fig. 5 . The NH acidity should be increased in the presence of fluorine atoms, thus a stronger interaction was expected if the hydrogen bond indeed plays an important role in the <x-GalCer/CDld interaction network; thereby the compound would induce a Thl cytokine polarisation based on the above-mentioned activation model. However, the compound turned out to be less potent than Cl-GaICer, inducing less IFN-y and similar levels ofIL-4, which suggests that the NH-ThrI54 hydrogen bond plays no major role in stabilizing the Cl-GaICer/CD Id complex. Instead, it was suggested that this bond may contribute to the orientation of the sugar headgroup. Recently, the amide bond of Cl-GalCer was substituted with a sulfonamide group by Mori and coworkers with the rationale that this conversion is one of the major processes in drug discovery. They synthesised a series of Cl-GalCer analogues with different aromatic and aliphatic sulfonamide structures,n as exemplified in Fig. 6 , and examined their immunostimulatory effect. All the compounds turned out to be less active in terms of IFN-y release, but most of them could induce effectively the production of IL-4 favoring Th2-biased cytokine production. Among them the pacetamidobenzenesulfonamide analogue (Fig. 6) showed the highest value of IL-4/IFN-y ratio. Possibly, the bulky aromatic ring would not fit well into the binding groove of CD I d leading to the very Iow stability of the complex, thereby undermining their stimulatory activities, but it is not clear why the aliphatic sulfonamide analogue exhibited similar activities. As the amide group of Cl-GalCer does not play a key role in binding with CDld and especially the carbonyl group of the amide does not seem to be involved in hydrogen bonding, recently, Kim and coworkers replaced the amide functionality by a triazole. 93 The resultant triazole-containing rx-GalCer analogues proved to bias cytokine secretion towards the Th2 response, and long-chain analogues have a comparable stimulatory effect on cytokine production as rx-GaICer. Molecular modeling studies showed that the triazole analogues are quite similarly oriented as rx-GalCer in their crystalline complex with CDld; as such, the triazole seems capable of serving as a linking unit that can mimic the atom arrangement of the orignial amide group.
In addition, various rx-GalCer derivatives with modified fatty acyl chains have been synthesised in the past few years as chemical tools to study the interaction between rx-GalCer and the CDld receptor and to visualize the in vivo behaviour of rx-GaICer. At early stage, Koezuka and co workers synthesised a number of rx-GalCer derivatives with biotin attached to the fatty acyl chain (as exemplified by structure I in Fig. 7 ) in order to study their binding with CDld and distribution in APCs. 94 All the biotinylated rx-galactosylceramides were found to be effective ligands for CD Id, but with limited capacity. Binding between rx-GalCer and CDld could be attenuated after biotinylation due to the lack of space in the A' pocket to accommodate the biotin moiety resulting in the disruption of hydrogen bonds and alteration of the rx-GalCer presentation to the TCR. Subsequently, they synthesised another rx-GalCer derivative with a fluorescent group, 7-nitrobenz-2-oxa-I,3-diazole (NBD) group, at the end of the fatty acyl chain (structure 11 in Fig. 7) . 95 This compound displayed very strong stimulatory effect on the proliferation of murine spleen cells, predicting a potency that is IO-fold stronger than that of ex-GaICer. This suggests that structure 11 could be a useful tool for the study of the antigenpresenting pathways related to CD Id-like molecules. Recently, another fluorescent group, boron dipyrromethine difluoride (BODIPY), was also introduced into the fatty acyl chain of a sphinganine-based ex-GalCer analogue by Bonin and coworkers. 96 The resultant molecule (structure III in Fig. 7 ) proved to be almost as active as ex-GalCer for inducing in vivo apoptosis of liver NKT cells.
As the installation of biotin or fluorescent tags are very likely to alter ex-GalCer binding properties, Ovaa and coworkers synthesised a tritiumlabeled ex-GaICer, structure IV (Fig. 7) . 97 Eight tritium atoms were incorporated into the fatty acyl chain after the construction of the whole skeleton of ex-GalCer by catalytic reduction of an unsaturated bisacetylene precursor using tritium gas. This radiolabelling should facilitate pharmacokinetical studies of ex-GalCer and quantitative analysis of the interaction between ex-GalCer and the CD Id receptor.
Modification of the sugar ring
As mentioned in the introduction, ex-GalCer protrudes minimally from the COld cleft with the galactose ring exposed for recognition by TCR. The X-ray structure 40 shows that the sugar ring is sandwiched between TrpI53 of COld and the aliphatic moiety of Arg95ex of the TCR CDR3ex loop. Apart from hydrogen bonding with COld, the 2-, 3-and 4-0H of the galactose ring also form hydrogen bonds to Gly96ex, Ser30ex, and Phe29ex, respectively, which are located on the invariant TCR ex-chain. These hydrogen bonds are responsible for the fine specificity that the NKT TCR exhibits for ex-GalCer and its closely related analogues. Only the 6-0H group of the sugar ring is not involved in any hydrogen bond formation during ex-GalCer binding and recognition. Therefore, modifications of the 6-OH group are often acceptable and have no considerable influence on the bioactivities of ex-GaICer; but most modifications of the 2-, 3-and 4-0H groups are not tolerated, leading to a decrease or loss of the bioactivities. In addition, the ex-anomeric configuration of ex-GalCer is critical for NKT cell recognition as the corresponding ~-anomer has a significantly reduced ability to stimulate NKT ceIls 98 ,99 or no effect at all. 36, 80, 95, 100 In this section, we will highlight some important structural modifications conducted recently towards the sugar ring of ex-GaICer.
3.4.1 Modification at the 2-position of the sugar moiety. ex-MannosyIceramide was synthesised and tested as NKT ceII stimulant. It displayed no stimulatory activity at all, probably because the axial 2-0H group of the mannose could potentially clash with TCR.
8o The configuration of the 2-0H group is therefore also essential for NKT cell recognition. Introduction of an extra galactose onto 2-0H also reduced the immunostimulatory activity of ex-GaICer. 80 Later it was found that the Galex(l-7 2)GalCer was actually not active itself, it was processed by APCs under removal of the extra galactose to generate the antigenic epitope before it was presented to For the synthesis, a galactosyl acetate and a tritylated azidophytosphingosine were used as the donor and acceptor, respectively, and the et-glycoside was produced in very good yield. This analogue exhibited significantly reduced activity, suggesting that a free OH group at 2-position is also essential for the immunostimulatory activity of et-GaICer.
In addition, a range of other et-GalCer analogues with 2-0H modification have also been synthesised, such as 2-deoxy,103 2-fluoro and 2-deoxy-2-acetamido galactosylceramides,81 and not unexpectedly, most of them lost completely the activities.
3.4.2 Modification at the 3-and 4-position of the sugar moiety. So far not much structural modification has been carried out towards the 3-and 4-position of the sugar ring of et-GaICer, but it seems that NKT cell response is slightly less sensitive to the modification of these positions than the 2-position as some modifications such as sulfation at 3-0H are tolerated. Wong et al. reported that the 3-0-sulfate of et-GalCer could efficiently stimulate human NKT cells to secrete IL-4 and IFN-y, with activities similar to those of et-GaICer. 104 However, glycosylation of the 3-0H group could result in a dramatic decrease in activities, and like 2-0-glycosylated etGalCer, the additional sugar needs also to be cleaved by the corresponding enzyme before recognition by NKT cells.
IOI Very recently, Howell and co workers synthesised 3-deoxygalactosyl and 3-deoxy-3-fluorogalactosyl sphinganine analogues and assessed their antigenic potency against three well-characterized NKT cell hybridomas. Both compounds were immuno stimulatory but turned out to be weaker antigens than et-GalCer in terms of the amount of relea'sed IL_2. 105 et-Glucosylceramide was found less potent than et-GalCer in inducing proliferative responses of NKT cells.
8o The configuration of the 4-0H group is thus possibly important for keeping high activity. However, a free 4-0H is not essential for activity as a 4-0-glycosylated glycosphingolipid isolated from the marine sponge exhibited a stimulatory activity comparable to that of agelasphin. 106 Also, the 4-deoxy-4-fluorogalactosyl sphinganine analogue displayed strong stimulatory activity and it is even more potent than <x-GalCer in inducing IL-2 release. Nevertheless, the corresponding 4-deoxy analogue is a very weak antigen. 105 Therefore, both 3-and 4-0H groups have a clear influence on the activity of <x-GalCer, but they are less influential than the 2-0H group. This suggests that the above-mentioned different hydrogen bonds involving these OH groups do not make equal contributions to the potency of <x-GalCer.
3.4.
3 Modification at the 6-position of the sugar moiety. Comparatively, a lot more structural modifications have been conducted at the 6-position of the sugar part of <x-GalCer as the crystal structure reveals that this hydroxyl group is located in a large open pocket, thus structural variations should not harm the biological activities. For instance, an extra galactose was introduced at the 6-position of <x-GalCer and the resultant disaccharide ceramide could act directly as effective antigen without removal of the additional galactose. 101 Prior to this, it was also found that 6-0-galactosylated <x-GalCer could induce effectively proliferative responses of NKT cells. 8o Recently, Savage and coworkers synthesised a group of <x-GalCer derivatives with fluorophore or biotin tags connected via amide bonds to the 6-position (Scheme 17) thus providing a means of quantifying the association of <x-GalCer with CDld and TCR. All the compounds were found to retain the NKT cell stimulating properties, and the biotin-labeled one (Scheme 17) was even more effective than <x-GaICer in inducing IL-2 release. As such, the attachments at 6-position do possibly not interfere with TCR recognition. Based on this work, Savage et al. further modified <x-GalCer by introducing an acetamido group and a double bond into the 6-position of the sugar and the fatty acyl chain, respectively, with a view to improve the solubility of <x-GaICer. 108 Interestingly, the resultant analogue could stimulate NKT cells in vitro at lower concentrations than ex-GaICer, and in vivo it was at least as effective in inducing cytokine release.
More recently, van Calenbergh synthesised a series of 6-derivatised ex-GalCer analogues following a strategy similar to Savage's in order to investigate whether extra interactions with CD I d could be introduced. 109 Most analogues are capable of shifting the cytokine release profile to Th I and possess a comparable ability to induce IFN-y release as ex-GaICer. The most promising one was a compound featuring a 3-CF3, 4-CI-benzamide substituent at 6-position, which could produce similar levels of IFN-y but only marginal levels of IL-4. It was proposed that the aromatic substituents at the 6-position may be involved in additional hydrophobic interactions, which increase binding with CDld, resulting in Thl polarization. It is noteworthy that in the proximity of the 6-position hCDld contains a Trp 153 residue,11O as such, 1t-1t interaction between this tryptophan and aromatic groups at the 6-position could account for the enhanced binding.
Very recently, another series of ex-GalCer analogues was synthesised by Mori and coworkers, in which 6-0-alkylated galactoses and 6-deoxy or 6-deoxy-6-fluorosugars were used as sugar building blocks. III All the compounds were found to be more potent stimulants than ex-GalCer to induce a large amount ofIFN-y in mice il1 vivo. Interestingly, they induced maximum production of IFN-y 24 h after injection, while in the case of ex-GalCer the maximum was observed after 12h. As these analogues lack the 6-0H group which makes intramolecular hydrogen bonding with the 4-0H group, the authors ascribed the enhanced activity to the increased stability of CDldligand-TCR complex due to the increased electron density at the 4-0H group. Of them, the 6-0-methylated analogue was the most potent and was selected as the lead compound.
The flexibility of the 6-0H group has also been corroborated by the fact that NKT cells also recognize glycosphingolipids containing ex-linked galacturonic or glucuronic acid residues. 38 , 77 The alteration caused by having 6-0H oxidized to a carboxylic acid caused very little changes in NKT cell reactivity.81
ex-C-Galactosylceramides
o:-C-GaICer
Due to the inherent in vivo instability of O-glycosides, Franck and coworkers synthesised a C-glycosyl analogue of ex-GaICer, 112 and examined its biological activities. Surprisingly, this anomeric analogue (ex-C-GaICer) exhibited a IOOO-fold more potent antimalaria activity and a lOO-fold more potent antimetastatic activity than ex-GaICer. 113 Compared with ex-GaICer, the C-glycosyIceramide consistently stimulated prolonged production of the T HI cytokines and decreased production of T H2 cytokines, which suggests that ex-C-GaIger may be an excellent therapeutic option for diseases resolved by T HI responses. The high activities of ex-C-GaICer also led the investigators to evaluate its potential as an adjuvant for a live attenuated influenza virus vaccine. 5 The results showed that this C-glycosyIceramide reduced both morbidity and mortality in mice after challenge with the wild type influenza virus. Also, it could increase humoral and cellular immune responses to the vaccine and reduced the amount of virus required to protect mice. It is surprising indeed that a-C-GalCer displayed such high activities because the anomeric oxygen forms a hydrogen bond with CDld Thrl54, and its substitution by carbon would abrogate this interaction.
Recently, a review has been published on the synthesis and immunological activities of a-C-galactosylceramides.11 4 Hence, we will only highlight some important and very recent advances in the chemistry of a-CGalCer. Yet, it is clear by now that a-C-GalCer can induce a potent and a prolonged Th I cytokine profile in mice. However it was found unable to induce a significant level of cytokine production by human NKT cells. I IS Initially, a-C-GalCer was synthesised from commercially available Lhomo serine in a linear sequence of 26 steps, as outlined in Scheme 18. 112 In the synthesis, the Ramberg-Backlund rearrangement was employed as a key step to introduce the anomeric carbonic linkage, and an intramolecular hydride transfer was utilized to establish the desired a-anomeric configuration.
TBSO~C,.H29 Another more efficient synthesis featuring olefin cross metathesis was reported shortly afterwards by the same group. 116 As shown in Scheme 19, in the presence of ethylene, the 2nd generation Grubbs' catalyst-promoted metathesis reaction effectively merged the vinyl galactoside with the vinyl derivative of phytosphingosine. This new synthetic route exhibited very high efficiency with an overall yield of 30% after II steps starting from commercially available phytosphingosine. This procedure could be readily scaled up to provide larger quantities of a-C-GaICer for biological studies. In this work, C-vinyl and C-allyl analogues were also synthesised along with the saturated derivatives, and assayed as immunostimulants. The biological data indicated that a certain distance between the galactose ring and the ceramide is essential for activity as analogues with a four-bond connector between anomeric carbon and the ceramide C-N precluded their recognition by CDld.
In view of the great potency of cx-C-GaICer, soon Wipf et al. developed another slightly shorter synthetic route which provided the C-glycosylceramide in a linear sequence of 10 steps and 22% overall yield, Il7 as outlined in Scheme 20. The route involved the installation of the chiral amino group by a diastereoselective alkenylmetal addition to an N-tert-butanesulfinyl imine and the use of a stereoselective trans-alkene epoxidation-intramolecular carbamate cyciization protocol to introduce the diol functionality. As mentioned in the introduction, CDld-bound cx-GalCer displays an "anti" dihedral angle of '" 170 0 in the linker region between the galactose and the ceramide. Very possibly, the anomeric CH 2 in cx-C-GaJCer causes conformational alterations of the CD I d-binding surface, hence it is less well recognized by NKT cell receptors. To evidence the COld-binding geometry of <x-GaICer, as part of his C-glycosylation chemistry, Franck et al. synthesised recently a series of <x-C-GaICer analogues with a cis or trans double bond in the linker region, in which a one-pot version of the Julia olefination approach was employed to synthesise both (E)-and (Z)_isomers. 115 ,118 The (E)-isomer was produced exclusively by using the benzothiazol-2-yl (BT) sulfone building block, as exemplified in Scheme 21. The (Z)-isomer was so far formed in very low stereoselectivity. Scheme 21 Franck's synthesis of (E)-a-C-GaICer
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In the ensuing bioassay, the E isomer proved to be far more potent than the Z isomer as a ligand for the CDldjNKT pathway, and it not only exhibited activity in mice, but also induced a potent stimulatory activity against human NKT cells. Hence, the {rans double bond linker may restore the best conformation of the sugar moiety, thus allowing the analogue to be recognized well by the TCR of both human and mouse NKT cells. Moreover, the (E)-isomer turned out to be a stronger inducer ofIL-12 than the original <x-C-GaICer, IL-12 is secreted by the dentritic cells bearing the COld molecule. It could thus be inferred that the (E)-ligand may bind more securely to the COld than the more flexible saturated C-glycosyl compound, resulting in the stronger IL-12 signal. However, the (E)-isomer is a weaker inducer of IFN-y than <x-C-GaICer, which suggests that more flexibility may be required for very efficient recognition by the NKT cell receptor, which then leads to IFN-y production.
Recently, Bittman and coworkers synthesised another C-glycosyl analogue of <x-GaICer, 119 in which the glycosidic oxygen was deleted so that only one methylene group links the sphingoid chain with the sugar moiety. In the synthesis, the Sharpless kinetic resolution method was used to introduce simultaneously the three chiral centers in the sphingoid chain, as shown in Scheme 22. The whole synthetic route consists of 13 steps from galactose pentaacetate and afforded the target molecule in 4% overall yield. This analogue, albeit being a less potent agonist for human NKT cells than ex-GalCer and ex-C-GalCer, induced cytokine production with the highest IFN-y:IL-4 and IFN-y:IL-I3 ratios in vitro, i.e. promoted preferentially Th I-immune responses. It may thus serve as a potent adjuvant in the immunotherapy of cancer and infectious diseases. A C-glycosyl analogue of immunomodulating ex-galactosylceramide OCR was also synthesised recently by Annoura et af. for studying SAR of ex-GalCer. 120 The key step in the synthesis is a nucleophilic addition of an ex-ethynyl galactose to a phytosphingosine-precursor aldehyde, derived from L-arabinose. Unlike ex-OCR, ex-C-OCR did not show in vitro IL-4 and IFN-y production in splenocytes but did increase serum levels of IL-4 in C57BL/6 mice in vivo. In addition, other C-linked galactosylceramides, such as ~-C-Gal Cer l21 and sulfonamide-based C-glycosyl analogues,92 have also been synthesised, but no promising bioactivities have been reported.
ex-S-GaICer
In some cases, the diminished activities of C-glycosyl compounds have been ascribed to the lack of the anomeric oxygen which can form a hydrogen bond with CD Id.92 As such, it would be interesting to investigate other ex-GalCer analogues with enhanced enzymatic stability but retaining possibly the hydrogen bond. In this context, thioglycosides are very attractive substitutes for O-glycosides as it is well known that they are much less susceptible to enzymatic cleavage as well as chemical degradation, 122 moreover, their anomeric sulfur may possibly interact with COld through hydrogen bond. As a matter of fact, the thioglycoside strategy has been an active subfield of research in carbohydrate chemistry in the past few decades. 123 Recently, Zhu et al. achieved the first total synthesis of the thioglycoside analogue of <x-GaICer by using a nonconventional approach (Scheme 23). 124 The synthesis relied on a newly developed procedure for the preparation of <x-glycosyl thiols reported by the same group.125 Following the procedure, the <x-galactosyl thiol was prepared from the benzylated 1,6-anhydrogalactose in very high yield, and then coupled with the electrophilic sphingoid iodide under phase transfer conditions,126 to give the <x-linked product in very good yield. Notably, the <x-galactosyl thiol was produced exclusively as <x-anomer, which made the purification very simple and straightforward. This ring-opening procedure is a significant advance in glycosyl thiol chemistry because there have not been any reports on direct stereospecific preparation of <x-glycosyl thiols prior to this work. Eventually the <x-S-GalCer was synthesised in a linear sequence of 14 steps and 3% overall yield. Bioassay of <x-S-GalCer is in progress, The preliminary data show that it is a potent activator of NKT cells in CD Id-dependent manner. 127 Like <x-CGalCer, the thioglycoside also stimulated enhanced levels of the Thl cytokine IFN-)" and diminished levels of the Th2 cytokine IL-4 as compared with <x-GaICer. Moreover, the thioglycoside primes COld-expressing target cells for killing by NKT cells more potently than <x-GaICer. As such, <x-S-GaICer may find use in modulating immune responses and in the treatment of certain diseases.
Jffl
As raised in C-glycosyl analogues, an important question is why <x-SGalCer exhibits a different cytokine release profile seeing that structurally there is only subtle difference from <x-GaICer. Thioglycosides have usually more flexibility around the anomeric linkage compared with the corresponding O-glycosides owing to the longer C-S bond and weaker stereoelectronic effects. Zhu et al. speculate that this increased flexibility might cause <x-S-GaICer to sit differently in the COld binding groove, resulting in an altered structure of the glycolipid/CD I d complex and a change in its affinity with the TCR of NKT cells. Also, after binding with CDld, the sugar head of ex-S-GaICer may orientate in a different angle from that of ex-GalCer as C-S-C bond angle is significantly smaller than the C-O-C angle, which could result in differential recognition by the TCR of NKT cells.
Almost at the same time, Rowell et al. also reported a similar synthesis of ex-S-GaICer,128 however, the construction of thioglycosidic bond is nonstereoselective as a mixture of ex-and J3-galactosyl thiols was used as the sugar building block and the desired ex-product was isolated after the coupling reaction. Surprisingly, their subsequent bioassay showed that ex-SGalCer induced no detectable cytokine or proliferative response. Molecular modelling studies indicated that three original hydrogen bonds formed between ex-GalCer and receptors appeared to be either absent or weakened in the ex-S-GaICerJprotein structure, which may be accountable for the loss of activity of ex-S-GaICer. The authors also suggest that the in vivo degradation or oxidation of ex-S-GaICer may be the reasons for the lack of activity. Apparently, further studies are needed to clarify the stimulatory activity of ex-S-GaICer.
Very recently, another thioglycoside-based ex-GalCer analogue was synthesised efficiently together with O-linked counterparts by Murphy et al. 129 A chelation-induced anomerization strategyl30 developed by the same group was applied effectively to the synthesis, as shown in Scheme 24, and the target uronic acid based glycolipids were constructed in high stereoselectivity. A great advantage of the synthesis, especially for the O-linked uronides, is that it circumvented the conventional ex-uronidation strategy that could suffer from low yields and poor exJJ3 selectivity. 131,132
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~C'6H33 This carbocylic analogue showed a significant increase in IFN-y production and a decrease in IL-4 cytokine release compared with et-GaICer, which suggested again that the augmentation of stability of sugar-ceramide linkage may favor the production of Thl cytokines.
Besides the fine-tuning of iNKT cell activation in vivo, leading to a selective release of Th 1-or Th2-type cytokines, another desirable feature of new et-GalCer analogues is the ability to activate iNKT cells in such a way that therapeutic administration does not result in rapid loss of circulating zNKT cells, as found for et-GaICer, 29 or in activation-induced anergy. 99 Hence, based on the above mentioned crystal structure analyses 37 ,38,40,135 Schmidt et al. designed analogues with specifically altered head groups,136,137 in order to address these aspects.
The crystal structure determinations of mouse and human COld with and without <x-GaICer and TCR showed that hydrogen bonds with the anomeric oxygen atom and the 2-and 3-hydroxy group of the galactose residue are important for the binding of polar head groups. 37,38 Therefore, compounds containing the L-threo configuration of the galactosyl residue at C-2 and C-3 (Scheme 26, Z = CH 2 0H) and closely related compounds seemed to be ideal analogues of <x-GaICer. Thus, also an increase in metabolic stability can be readily gained by having an ether linkage instead of an <x-glycosidic linkage to the ceramide residue. The saturated C 26 -fatty acyl chain fits quite well into the lipidic binding groove of COld. However, the bound conformer has dihedral angles that indicate that acyl chains with (Z)-configurated double bonds between C19-C20 and Cll-C23 should also be accommodated. As the structural analysis revealed that aromatic amino acids are located close to C-4 of the galactosyl residues a phenyl ring linked to C-4 (Z = PhCH 2 , Ph-CH(OH» could also lead to different binding characteristics. Hence, the compounds shown in Scheme 26 were the target molecules. They could be obtained from the alditol triflates as alkylating agents and 2-azido-3,4-0-isopropylidene-phytosphingosine 47 as the key step. Azido group reduction, introduction of the fatty acyl residue and complete deprotection led to the desired compounds. This novel ligands induce slightly lower levels of cytokines than does <x-GaICer, yet they maintain the ability to mature DCs. In in vivo and in vitro assays 80-90% of DCs pulsed with cr-GalCer were killed by lNKT cells, whereas a significantly lower proportion of DCs were lysed when treated with threitol-ceramide (Fig. 26 , Z = CH 2 0H). This compound was also an effective adjuvant for priming T and B cell responses to a model antigen. Thus, it should be highly useful for clinical applications such as cancer immunotherapy. Hence, it is now in development for clinical evaluation as adjuvant in vaccines against cancer and infectious deseases.
myo-Inositol with a meso structure is also an ideal precursor for cr-GalCer analogues when the ceramide residue is linked to C-5, thus leading to neoinositol derivatives (Scheme 27) having enantiotopic L-or o-arabino and -threo moieties. Replacement of the 6-hydroxy group, for instance by a sulfate group, could lead to a different biological behaviour because CDld contains an arginine residue close by. 37 Scheme 27 Inositol derived nonglycosidic analogues of (X-GaICer
Conclusion
Activation of NKT cells via CDld-cr-GalCer-TCR interaction leads to the release of both T helper type 1 (Thl) and T helper type 2 (Th2) cytokines. As a result, NKT cells have the ability to either enhance or suppress Thl antigen-specific immune responses, such as virus-and tumour-specific immune response. Hence, structural variations of the lipid chain, of the phytosphingosine residue, of the sugar moiety and/or the glycosidic linkage in this molecule have been carried out as described in this review. Thus, different affinities for CD Id or the NKT cell receptor were found and shown to polarize NKT cells differently, enhancing the response to proinflammatory bacterial, viral and parasitic infections and some kinds of cancer, or suppressing autoimmune diseases in vitro and in vivo. Particularly noteworthy in this regard are nonglycosidic analogues of cr-GalCer that reduce overactivation of NKT cells and subsequent off-target effects such as cytokine production and NKT cell mediated dendritic cell (DC) lysis while maintaining the ability to induce DC maturation and priming of antigen-specific immune responses. Hence, this field is now in the stage for clinical evaluation of cr-GalCer derived lead compounds as adjuvants in vaccines against cancer and infectious diseases.
